Skip to main content
TipRanks
Go Ultimate75% OFF

Veracyte (12V) Q3 2026 Earnings Report

3 Followers

DE:12V Q3 2026 EPS Results

Actual EPS
EUR 0.46
Consensus EPS
EUR 0.37
Beat/Miss
Beat by +EUR 0.09
One Year Ago EPS
EUR 0.46

DE:12V Q3 2026 Revenue Results

Actual Revenue
EUR 138.06M
Expected Revenue
EUR 133.85M
Beat/Miss
Beat by +EUR 4.20M
YoY Revenue Growth
+15.08%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/04/2026
Time
After Close
Conference Call
Wednesday, November 4, 2026
DE:12V Upcoming Earnings

Veracyte's next earnings date is estimated for March 1, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:12V Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 04, 2026|% Change Since:-52.31%|
Earnings Call Sentiment|Positive

The call was positive overall, supported by 15% third-quarter revenue growth, strong profitability and cash generation, Afirma outperformance, expanding clinical evidence for Decipher, Prosigna reimbursement and adoption progress, new bladder cancer capabilities, and a $100 million share repurchase authorization. However, management moderated near-term expectations because Decipher growth is normalizing, low-risk utilization has slowed, competitive activity is distracting the sales force, 2026 revenue guidance was reduced, and 2027 revenue growth is expected to be only mid-single digit with adjusted EBITDA below the long-term target. The highlights significantly outweighed the lowlights.

Company Guidance

For 2026, Veracyte expects full year revenue of $590 million to $593 million, up 14% to 15% year-over-year, testing revenue of $571 million to $573 million, up 16%, approximately $10 million in other testing revenue, 16% Decipher prostate revenue growth with full year ASP slightly above 2025 and fourth-quarter volume roughly flat sequentially, Afirma revenue growth of 16% versus 12% to 14% previously, an expected 3% full year no result rate benefit, and adjusted EBITDA above 26%; for 2027, Decipher volume growth is expected near the 12 thousand incremental test floor, Afirma volume growth is expected at 5%, total volume growth at 10%, total revenue growth at mid single digit total revenue growth, and adjusted EBITDA at 22% for the full year, with Q1 representing the low point due to expense timing before margins improved to 25% as we exit the year, while the long-term adjusted EBITDA goal remains unchanged at 25%; Decipher’s incremental annual volume growth expectations are 12 thousand to 15 thousand tests with the low end as a reasonable floor for now.

  • Third-Quarter Revenue and Profitability GrowthThird-quarter revenue increased 15% year-over-year to $152 million, while total testing volume increased 15% to approximately 52.7 thousand tests. GAAP net income was $31.5 million, adjusted EBITDA was $41.2 million, or 27.2% of revenue, exceeding the company’s 25% annual long-term target.
  • Strong Cash Generation and Balance SheetVeracyte generated $40.3 million of cash from operations and ended the quarter with $371 million in cash, cash equivalents and short-term investments after making a $150 million cash payment for the Convergent Genomics acquisition.
  • Testing Revenue, ASP and Gross Margin ExpansionTesting revenue grew 15% year-over-year to $146 million, testing volume increased 13% to 49.5 thousand tests, and ASP increased 1% to $2.96 thousand, including approximately $2.5 million in prior-period collections. Excluding prior-period collections, normalized ASP rose 2% to approximately $2.9 thousand. Non-GAAP gross margin increased 90 basis points to 73.7%, while testing gross margin rose approximately 70 basis points to 74.7%.
  • Afirma Outperformance and Utilization GainsAfirma delivered approximately 19 thousand tests, representing 12% year-over-year growth, driven by deeper utilization among existing physicians and continued share gains. It achieved its strongest sequential third-quarter volume increase since 2020. The V2 transcriptome workflow reduced the no-result rate and contributed approximately 300 basis points to year-over-year volume growth during the quarter.
  • Raised Afirma Revenue GuidanceThe company raised full-year 2026 Afirma revenue growth guidance to 16% from 12% to 14%, reflecting third-quarter outperformance, favorable year-to-date prior-period collections, continued ASP improvement and an expected 3% full-year no-result-rate benefit.
  • Decipher Continued Growth and New Clinical EvidenceDecipher prostate delivered nearly 30 thousand tests in the third quarter, representing 12% year-over-year growth. The company reported three new predictive claims in recent months, including evidence from the Phase 3 NRG RTOG 0815, STAMPEDE and ENZAMET studies across intermediate-risk, very-high-risk nonmetastatic and metastatic hormone-sensitive prostate cancer settings.
  • Decipher Evidence Pipeline and Product ExpansionThe Phase 3 GUIDANCE and PREDICT-RT randomized trials are fully enrolled, and the NCI-sponsored Phase 3 and G-MAJOR low-risk studies could begin reporting preliminary findings as early as next year. Veracyte is also bringing clinically validated PORTOS, PTEN and PAM50 signatures into its molecular features report and expects its first publication on the DPAI algorithm in the next few quarters.
  • Expanded Urology Commercial InvestmentVeracyte plans to expand its urology team by 30% next year across field representatives, medical science liaisons and sales leadership. The company said the investment will support Decipher prostate while also expanding commercial coverage for Decipher Bladder, TrueMRD and, over time, UroAmp.
  • Prosigna Launch and Clinical DifferentiationProsigna was launched in the United States following the Phase 3 OPTIMA readout, which provided Level I evidence and identified more than two-thirds of clinically high-risk women who could safely avoid chemotherapy. Prosigna is supported by 157 publications, while the PAM50 classifier on which it is built has more than 1.2 thousand publications.
  • Prosigna Commercial and Reimbursement ProgressThe company reported encouraging early U.S. demand for Prosigna, is on track to grow its dedicated medical oncology commercial team to 15 representatives by year-end, and recently secured Medicare reimbursement for eligible postmenopausal women with early-stage ER-positive breast cancer and zero to three positive nodes. Outside the U.S., Prosigna product revenue grew 40% year-over-year, driven primarily by adoption in the UK and Nordic region.
  • Bladder Cancer Portfolio ExpansionThe Convergent Genomics acquisition added UroAmp, a urine-based tumor DNA platform, to Veracyte’s bladder cancer portfolio. Together with tissue-based Decipher Bladder and blood-based TrueMRD, the company is building testing capabilities spanning diagnosis, treatment response, recurrence monitoring and post-treatment surveillance.
  • UroAmp Evidence and Commercialization PlanUroAmp has nine peer-reviewed publications and more than 40 abstracts and posters, with four additional abstracts accepted for the Society of Urologic Oncology meeting. Data from the prospective INSIGHT trial have been accepted for peer-reviewed publication, and the company expects to launch its first UroAmp application in late 2028 with Medicare reimbursement.
  • TrueMRD Launch and ReimbursementVeracyte launched its first commercial TrueMRD test earlier this year after securing Medicare reimbursement for recurrence monitoring in patients with muscle-invasive bladder cancer following radical cystectomy. The test uses whole-genome sequencing for both landmark testing and longitudinal monitoring.
  • One-Millionth Patient MilestoneDuring the quarter, Veracyte served its 1 millionth patient, which management described as a milestone reflecting the reach and impact of its tests.
  • Share Repurchase AuthorizationThe Board authorized a share repurchase program of up to $100 million.
  • Long-Term Portfolio Growth OutlookManagement said it expects growth to accelerate through 2027, 2028 and beyond as Decipher evidence expands across risk categories and newer breast and bladder growth drivers gain momentum. The company continues to view 80% market share and 80% penetration as achievable long-term targets for Decipher.

DE:12V Earnings History

DE:12V earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 01, 20272026 (Q4)0.34-0.48――
Nov 04, 20262026 (Q3)0.370.460.460.00% (+0.00)
Jul 30, 20262026 (Q2)0.370.490.422.73% (+0.09)
May 05, 20262026 (Q1)0.290.470.2867.74% (+0.19)
Feb 25, 20262025 (Q4)0.370.480.05783.33% (+0.43)
Nov 04, 20252025 (Q3)0.290.460.17168.42% (+0.29)
Aug 06, 20252025 (Q2)0.250.400.06528.57% (+0.34)
May 07, 20252025 (Q1)0.110.28-0.021650.00% (+0.30)
Feb 24, 20252024 (Q4)0.100.05-0.35115.38% (+0.41)
Nov 06, 20242024 (Q3)0.030.17-0.37146.34% (+0.55)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed